HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC) WHO RECEIVED FIRST-LINE (1L) TREATMENT: RESULTS FROM IMPACT UC II

被引：0
|
作者：
Bilen, M. A. [1 ]
Diessner, B. [2 ]
White, J. [2 ]
Kirker, M. [3 ]
Liu, F. [4 ]
Nguyen, A. [2 ]
Gharibian, N. [3 ]
Devgan, G. [3 ]
Katzenstein, H. [4 ]
Bhanegaonkar, A. [4 ]
机构：
[1] Winship Canc Inst Emory Univ, Atlanta, GA USA
[2] Optum, Eden Prairie, MN USA
[3] Pfizer, New York, NY USA
[4] EMD Serono, Rockland, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE390
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [21] Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
    Barthelemy, P.
    Thibault, C.
    Voog, E.
    Eymard, J-C.
    Ravaud, A.
    Flechon, A.
    Jaillon, C. Abraham
    Hilgers, W.
    Le Moulec, S.
    Chasseray, M.
    Pouessel, D.
    Amela, Y. E.
    Lorgis, V.
    Nicolas, E.
    Kazan, E.
    Denechere, G.
    Solbes, M-N.
    Lambert, P.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1341 - S1342
  • [22] Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX
    Dieguez, Gabriela
    Hirsch, Jared
    Cockrum, Paul
    Bhatt, Prachi
    Tomicki, Samantha
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
    Galsky, M. D.
    Retz, M.
    Siefker-Radtke, A. O.
    Baron, A.
    Necchi, A.
    Bedke, J.
    Plimack, E. R.
    Vaena, D.
    Grimm, M-O.
    Bracarda, S.
    Arranz Arija, J.
    Pal, S. K.
    Ohyama, C.
    Saci, A.
    Lambert, A.
    Krishnan, S.
    Azrilevich, A.
    Sharma, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy
    Galsky, Matt D.
    Moshier, Erin L.
    Krege, Susanne
    Lin, Chia-Chi
    Hahn, Noah M.
    Ecke, Thorsten
    Sonpavde, Guru
    Pond, Gregory Russell
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [25] US TREATMENT PATTERNS AND COSTS FOR PATIENTS WITH HEPATOCELLULAR CANCER WHO HAVE RECEIVED SORAFENIB AS FIRST-LINE THERAPY
    Stokes, Michael
    Liepa, Astra
    Chuang, Chien-Chia
    D'yachkova, Yulia
    Wang, Alan
    Boulanger, Luke
    Hunter, Craig
    Schwartz, Jonathan
    ANNALS OF ONCOLOGY, 2012, 23 : 58 - 58
  • [26] First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.
    Saxena, Akshat
    Bin Riaz, Irbaz
    Naqvi, Syed Arsalan Ahmed
    Bibi, Arifa
    Channar, Aneeta
    Tripathi, Nikita
    Khan, Muhammad Ali
    Raina, Ammad
    Khakwani, Kaneez Zahra Rubab
    Childs, Daniel S.
    Bryce, Alan Haruo
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
    Bilen, Mehmet A.
    Robinson, Scott B.
    Schroeder, Amy
    Peng, Jing
    Kim, Ruth
    Liu, Frank X.
    Bhanegaonkar, Abhijeet
    ONCOLOGIST, 2023, 28 (09): : 790 - 798
  • [28] Baseline characteristics and first-line (1L) treatment of patients with HER2+metastatic breast cancer (MBC) from the SystHERs registry
    Kaufman, P. A.
    Hurvitz, S. A.
    O'Shaughnessy, J.
    Mason, G.
    Yardley, D. A.
    Brufsky, A.
    Rugo, H. S.
    Cobleigh, M.
    Swain, S. M.
    Tripathy, D.
    Chu, L.
    Antao, V.
    Yoo, B.
    Jahanzeb, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] FIRST-LINE TREATMENT PATTERNS AMONG PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (LA/MUC): A SYSTEMATIC LITERATURE REVIEW
    Kearney, M.
    Zhang, L.
    Hubscher, E.
    Musat, M.
    Harricharan, S.
    Wilke, T.
    VALUE IN HEALTH, 2022, 25 (12) : S414 - S414
  • [30] BUDGET IMPACT ANALYSIS OF AVELUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS FIRST-LINE (1L) MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED (LA) OR METASTATIC UROTHELIAL CARCINOMA (MUC) IN TAIWAN
    Tsai, Y. C.
    Lin, A. Y.
    Huang, J.
    Wu, E.
    Liu, K.
    Palencia, R.
    Chang, J.
    Kearney, M.
    VALUE IN HEALTH, 2022, 25 (01) : S47 - S47
12345